- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05938205
Multicomponent Analysis of phYsical Frailty BiomarkErs: Focus on Mitochondrial Health - MAYBE (MAYBE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this double-blind randomised control trial, older men, and women resident in Verona (Italy) will be selected from the Geriatrics Nutritional Clinic of the Borgo Trento Hospital or were contacted by telephone. A specific medical screening was initially programmed to verify the criteria of recruitment.
Anthropometric and body composition In the morning, in a fasted state, body mass will be taken with an electronic scale (Tanita electronic scale BWB-800 MA) and stature will be measured with a Harpenden stadiometer (Holtain Ltd., Crymych, Pembs. UK); BMI will be calculated as weight (kg)/height (m)2. Thereafter, total and regional body composition will be evaluated by means of dual-energy X-ray absorptiometry (DXA) using a total body scanner (QDR Horizon W, Hologic, MA, USA; fan-bean technology, software for Windows XP version 12.4.2) according to the manufacturer's procedures. Furthermore, the ALMI will be calculated as the sum of lean mass of arms and legs divided by height squared.
Physical performance On the same day, the SPPB test will be used to assess functional performance of the lower extremities. Each participant will performed: 4 m at usual customary gait speed, a five repeated chair-stands test and three standing balance tests (side by side, semi-tandem and tandem).
A digital dynamometer (CAMRY, Digital Hand Dynamometer model: EH101) will be used to assess HGS and all measurements were conducted by the same operator. Before starting, participants will observe a demonstration of the test procedure and engage in two practice attempts.
Knee muscle strength measurements and analysis An isokinetic dynamometer (CMSi Cybex Humac Norm Dynamometer, Lumex, Ronkokoma, NY, USA) will be used to assess the isokinetic strength of knee flexors and extensors muscles.
Maximal isokinetic knee extension-flexion tests will be performed in a randomised sequence at 60, 90, 150, 180 and 210°ˑs-1. Trials will consist in three knee extension-flexion movements with 60 s-recovery. The maximal strength of knee extensors muscle will be calculated with the Hill's hyperbolic function. The isokinetic knee extension-flexion power will be calculated as the product between strength and velocity. Finally, for knee extensors, maximal muscle power expressed in Watt, will be calculated from the power-velocity curve.
1-RM assessment Before starting training intervention, participants will perform three sessions of familiarization with the resistance isotonic machines. High intensity strength exercise (Exe-H) protocol: All the participants will performed a supervised progressive resistance training protocol, three times per week, 1 hour per session. Each participant will performed the same strength training protocol, starting with 3 sets of 8-10 repetitions at 70% of 1-RM (month 1), with a progressive increase of intensity at 75% of 1-RM (month 2 and month 3), and 80% 1-RM that will be maintained for the rest period of intervention. The compliance will be define as the number of exercise sessions expressed in % of the target value. Each participant will must reach a compliance above the 70% to be included in the final analysis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Verona, Italy, 37126
- AOUI Verona
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants will be included in the study based on the following inclusion criteria:
- Older men and women between 60-80 years
- The presence of sarcopenic obesity was considered when the following two conditions were satisfied: Fat mass > 34.8% and FFM <90% of subject's ideal FFM.
- Resident in Verona (Italy)
- Stable weight in the previous 2 months
- Previously sedentary (less than one hour of exercise per week in the last 6 months)
- Signing of the informed consent for participation in the study
Exclusion criteria:
- Unstable angina or recent myocardial infarction
- Malignant or unstable arrhythmias
- Heart failure NYHA class > II
- Severe respiratory failure
- Severe heart valve disease (i.e severe aortic stenosis or insufficiency)
- Abdominal and/or thoracic aneurysm
- Recent intracerebral or subdural haemorrhage
- Poorly controlled arterial hypertension
- Presence of pacemakers or metal prostheses
- Severe chronic renal failure
- Symptomatic musculoskeletal pathology
- Symptomatic disc herniation, arthrosis, acute joint, tendon and ligamentous injuries, hip and/or knee prostheses recently placed (<6 months) or with joint instability, symptomatic or large inguinal or abdominal hernia
- Acute retinal detachment or bleeding
- Recent eye surgery (laser, cataract, retinal surgery, glaucoma surgery)
- History of malignant cancer within the previous 5 years
- Diagnosis of dementia
- Eating disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exe-H + placebo
high intensity physical exercise combined with placebo
|
Nutritional Placebo
high intensity physical exercise
|
Experimental: Exe-H + AA-1
high intensity physical exercise combined with low dose of aminoacids
|
high intensity physical exercise
low dose aminoacids
|
Experimental: Exe-H + AA-2
high intensity physical exercise combined with high dose of aminoacids
|
high intensity physical exercise
high dose aminoacids
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline 1-repetition maximum with isokinetic dynamometer at 5-months
Time Frame: Month0, Month5
|
Change in 1-repetition maximum test performed with isokinetic dynamometer in Kilograms
|
Month0, Month5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline Short Physical Performance Battery at 5-months
Time Frame: Month0, Month 5
|
Change in Short Physical Performance Battery Score
|
Month0, Month 5
|
Change from baseline in handgrip at 5-months
Time Frame: Month0, Month5
|
Change in upper limb muscle strength measured with handgrip in kilograms
|
Month0, Month5
|
Changesfrom baseline skeletal muscle mass at 5-months
Time Frame: Month0, Month5
|
Change skeletal muscle mass measured with DXA in kilograms
|
Month0, Month5
|
Change from baseline fat mass at 5-months
Time Frame: Month0, Month5
|
Change fat mass measured with DXA in kilograms
|
Month0, Month5
|
Change from baseline in mRNA at 5-months
Time Frame: Month0, Month5
|
Change mRNA dosage
|
Month0, Month5
|
Change from baseline in muscle power at 5-months
Time Frame: Month0, Month5
|
Change in isokinetic muscle power of the lower limbs in kilograms
|
Month0, Month5
|
Collaborators and Investigators
Investigators
- Study Director: Elena Zoico, PhD, Universita di Verona
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1956CESC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frailty
-
University of PennsylvaniaCompleted
-
Instituto Tecnologico y de Estudios Superiores...Not yet recruiting
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
The Hong Kong Polytechnic UniversityCompleted
-
Xijing HospitalUnknownFrailty SyndromeChina
-
Region ZealandUniversity of Southern DenmarkActive, not recruitingFrailty SyndromeDenmark
-
IRCCS Centro San Giovanni di Dio FatebenefratelliCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
University of ValenciaCompletedFrailty SyndromeSpain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States